CR6073A - Compuestos heterociclicos como inhibidores de enzimas de rotamasa - Google Patents

Compuestos heterociclicos como inhibidores de enzimas de rotamasa

Info

Publication number
CR6073A
CR6073A CR6073A CR6073A CR6073A CR 6073 A CR6073 A CR 6073A CR 6073 A CR6073 A CR 6073A CR 6073 A CR6073 A CR 6073A CR 6073 A CR6073 A CR 6073A
Authority
CR
Costa Rica
Prior art keywords
rotamasa
enzymes
inhibitors
heterociclical
heterociclical compounds
Prior art date
Application number
CR6073A
Other languages
English (en)
Inventor
Ian Kemp Mark
John Palmer Michael
Allen Sanner Mark
James Wythes Martin
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CR6073A publication Critical patent/CR6073A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invencion se refiee a derivados de 1- heteroaril-pirrolidina, piperidina y homopiperidina, y a procedimientos para su preparacion, intermedios usados en su preparacion, composiciones que los contienen y los usos de tales derivados
CR6073A 1998-07-21 1999-07-20 Compuestos heterociclicos como inhibidores de enzimas de rotamasa CR6073A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9815880.1A GB9815880D0 (en) 1998-07-21 1998-07-21 Heterocycles

Publications (1)

Publication Number Publication Date
CR6073A true CR6073A (es) 2004-04-29

Family

ID=10835920

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6073A CR6073A (es) 1998-07-21 1999-07-20 Compuestos heterociclicos como inhibidores de enzimas de rotamasa

Country Status (45)

Country Link
US (2) US6372736B1 (es)
EP (1) EP1100797B1 (es)
JP (2) JP3795329B2 (es)
KR (2) KR100450008B1 (es)
CN (3) CN1611499A (es)
AP (1) AP2001002046A0 (es)
AR (1) AR019427A1 (es)
AT (1) ATE233261T1 (es)
AU (1) AU765925B2 (es)
BG (1) BG105254A (es)
BR (1) BR9912330A (es)
CA (1) CA2338214C (es)
CO (1) CO5080782A1 (es)
CR (1) CR6073A (es)
DE (1) DE69905582T2 (es)
DK (1) DK1100797T3 (es)
DZ (1) DZ2851A1 (es)
EA (1) EA003513B1 (es)
EE (1) EE200100044A (es)
ES (1) ES2191484T3 (es)
GB (1) GB9815880D0 (es)
GE (1) GEP20033028B (es)
GT (1) GT199900115A (es)
HK (1) HK1039779A1 (es)
HN (1) HN1999000106A (es)
HR (1) HRP20010052A2 (es)
HU (1) HUP0103413A3 (es)
ID (1) ID26991A (es)
IL (1) IL140244A0 (es)
IS (1) IS5790A (es)
MA (1) MA24936A1 (es)
MY (1) MY118222A (es)
NO (1) NO20010322L (es)
NZ (2) NZ522270A (es)
OA (1) OA11585A (es)
PA (1) PA8478501A1 (es)
PE (1) PE20001037A1 (es)
PL (1) PL345734A1 (es)
SI (1) SI1100797T1 (es)
SK (1) SK772001A3 (es)
SV (1) SV1999000102A (es)
TN (1) TNSN99147A1 (es)
TR (1) TR200100135T2 (es)
TW (1) TWI229672B (es)
WO (1) WO2000005232A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
TR200101239T2 (tr) 1998-11-03 2001-11-21 Basf Aktiengesellschaft İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
DE10124953A1 (de) * 2001-05-21 2002-12-12 Marlies Knipper Substanz für die therapeutische Behandlung von Tinnitus
JP4812758B2 (ja) * 2004-06-29 2011-11-09 アベンティス・ファーマスーティカルズ・インコーポレイテツド Fkbp結合組成物及びその医薬上の使用
US7728026B2 (en) * 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
CN101316834A (zh) * 2005-09-29 2008-12-03 艾博特公司 在2位取代有苯基的1h-苯并咪唑-4-甲酰胺是强效parp抑制剂
JP5162465B2 (ja) * 2005-11-15 2013-03-13 アボット・ラボラトリーズ 置換1h−ベンズイミダゾール−4−カルボキサミド類は強力なparp阻害薬である
EP3205644A1 (en) 2005-12-29 2017-08-16 Celtaxsys Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
BRPI0707719A2 (pt) 2006-02-10 2011-05-10 Summit Corp Plc uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo
RU2462458C2 (ru) * 2006-02-10 2012-09-27 Байомарин Ига Лимитед Лечение миодистрофии дюшена
GB0602768D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
MX2008014004A (es) * 2006-05-02 2008-11-12 Abbott Lab 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.
MX2009006543A (es) * 2006-12-20 2009-06-26 Amgen Inc Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
CL2008000666A1 (es) * 2007-03-07 2008-06-13 Xenon Pharmaceuticals Inc Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro.
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
AU2008285289A1 (en) * 2007-08-03 2009-02-12 Biomarin Iga Limited Drug combinations for the treatment of Duchenne muscular dystrophy
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
GB0715939D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
WO2010083199A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
GB0905664D0 (en) * 2009-04-02 2009-05-13 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
MX2015011678A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
AU2014240042C1 (en) 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
EP2968265A4 (en) 2013-03-14 2016-12-28 Celtaxsys Inc INHIBITORS OF THE LEUKOTRIEN A4 HYDROLASE
NZ726874A (en) * 2014-05-19 2018-03-23 Merial Inc Anthelmintic compounds
EP3801559B1 (en) 2018-05-31 2025-01-01 Celltaxis, LLC Method of reducing pulmonary exacerbations in respiratory disease patients
CN109111376B (zh) * 2018-09-18 2021-09-14 四川医立特生物医药有限公司 一种2,5-双脱氧链霉胺衍生物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612332A (en) * 1984-03-19 1997-03-18 Alteon Inc. Di- and triaminoguanidines, and methods of use
JPS6428245A (en) 1987-07-22 1989-01-30 Sumitomo Electric Industries Production of fluoride glass
MX9202466A (es) 1991-05-24 1994-06-30 Vertex Pharma Compuestos inmunosupresores novedosos.
CO4520280A1 (es) * 1993-10-26 1997-10-15 Boehringer Ingelheim Pharma Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos
DE19514313A1 (de) 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5859031A (en) 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5801197A (en) * 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5786378A (en) * 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US5801187A (en) * 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US5780484A (en) 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5811434A (en) 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
US5721256A (en) 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles

Also Published As

Publication number Publication date
TNSN99147A1 (fr) 2005-11-10
IS5790A (is) 2000-12-22
BR9912330A (pt) 2001-04-17
TR200100135T2 (tr) 2001-06-21
ID26991A (id) 2001-02-22
CO5080782A1 (es) 2001-09-25
NZ522270A (en) 2004-03-26
TWI229672B (en) 2005-03-21
CN1174978C (zh) 2004-11-10
HUP0103413A2 (hu) 2002-05-29
JP2002521382A (ja) 2002-07-16
MY118222A (en) 2004-09-30
GEP20033028B (en) 2003-07-25
DK1100797T3 (da) 2003-04-22
DE69905582D1 (de) 2003-04-03
KR20010071013A (ko) 2001-07-28
NZ508838A (en) 2002-12-20
GB9815880D0 (en) 1998-09-16
EE200100044A (et) 2002-06-17
DZ2851A1 (fr) 2004-02-04
SK772001A3 (en) 2001-12-03
HRP20010052A2 (en) 2001-12-31
WO2000005232A1 (en) 2000-02-03
EP1100797A1 (en) 2001-05-23
KR20040062640A (ko) 2004-07-07
EA200100052A1 (ru) 2001-06-25
KR100450008B1 (ko) 2004-09-24
SV1999000102A (es) 2000-07-06
CA2338214A1 (en) 2000-02-03
HK1039779A1 (zh) 2002-05-10
SI1100797T1 (en) 2003-06-30
ATE233261T1 (de) 2003-03-15
PL345734A1 (en) 2002-01-02
JP3795329B2 (ja) 2006-07-12
HUP0103413A3 (en) 2002-10-28
NO20010322D0 (no) 2001-01-19
EP1100797B1 (en) 2003-02-26
AP2001002046A0 (en) 2001-03-31
EA003513B1 (ru) 2003-06-26
KR100468185B1 (ko) 2005-01-26
DE69905582T2 (de) 2003-09-04
CN1310718A (zh) 2001-08-29
GT199900115A (es) 2001-01-10
IL140244A0 (en) 2002-02-10
CN1611499A (zh) 2005-05-04
PE20001037A1 (es) 2000-10-11
PA8478501A1 (es) 2000-05-24
US6562964B1 (en) 2003-05-13
HN1999000106A (es) 1999-11-11
JP2004002374A (ja) 2004-01-08
NO20010322L (no) 2001-03-15
CA2338214C (en) 2006-08-01
AR019427A1 (es) 2002-02-20
AU765925B2 (en) 2003-10-02
MA24936A1 (fr) 2000-04-01
ES2191484T3 (es) 2003-09-01
BG105254A (en) 2001-10-31
CN1511837A (zh) 2004-07-14
AU4285899A (en) 2000-02-14
US6372736B1 (en) 2002-04-16
OA11585A (en) 2004-07-26

Similar Documents

Publication Publication Date Title
HN1999000106A (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
HN2003000064A (es) Derivados de nicotinamida utiles como inhibidores de pde4
HN2003000062A (es) Derivados de nicotinamida utiles como inhibidores de pde4
AR008861A1 (es) COMPUESTOS DE LACTAMA E IMIDA HETEROCICLICOS DE ARALQUILO Y ARALQUILEDENO, COMPUESTOS INTERMEDIARIOS PARA SU SíNTESIS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN.
HN2003000114A (es) Derivados del tropano utiles en terapia
UY24986A1 (es) Compuestos
HN2004000538A (es) "PIRIDO[ 2,3-d ] PIRIMIDINA-2,4-DIAMINAS COMO-INHIBIDORES DE PDE 2"
SV2003000925A (es) Derivados espirotriciclicos nuevos y su uso como inhibidores de fosfodiesterasa-7
HN2000000204A (es) Derivados de la purina
PA8693101A1 (es) Compuestos de isoindol-imida y composiciones que los incluyen y mètodos para su uso
GT199700015A (es) Inhibidores de metaloproteinasa, composiciones farmaceuticas que las contienen y su uso farmaceutico y metodosyeficazproducto intermedio para su preparacion.
SV2001000004A (es) Difenil ureas w-carboxyaril sustituidas, composición farmacéutica que las comprende y su uso como inhibidores de raf quinasa
ES2043625T3 (es) Derivados de acido ariloxicarboxilico, su preparacion y empleo.
ES2196377T3 (es) Derivados de naftiridina.
ATE273690T1 (de) Zusammensetzung zur hautdesinfizierung
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
BR9916004A (pt) Inibidores de proteinase c de pró-colágeno
ES2154318T3 (es) Agentes antitromboticos.
UY28048A1 (es) Inhibidores de hiv-integrasa,composiciones farmacéuticas y métodos para su uso
ES2160680T3 (es) Utilizacion de un antagonista de sustancia p en una composicion farmaceutica.
GT200400143A (es) Compuestos
ES2187738T3 (es) Derivados de flavonas, su procedimiento de preparacion y los compuestos farmaceuticos que las contienen.
ES2147427T3 (es) Aminas ciclicas n-sustituidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
HN2001000235A (es) Derivados puentes de piperazina
HN2000000045A (es) Nuevas combinaciones farmaceuticas para inhibidores de la nos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)